![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cobra Bio-Man. | LSE:CBF | London | Ordinary Share | GB0031704835 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.25 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Cobra Bio-Manufacturing PLC 18 January 2007 For Immediate Release 18 January 2007 Cobra Biomanufacturing Plc Cobra signs agreement with Cequent to evaluate Cobra's ORT Technology for RNAi Delivery Keele, UK, 18 January 2007 - UK based Cobra Biomanufacturing Plc (AIM: CBF) has signed an agreement with Cambridge, MA based Cequent Pharmaceuticals, Inc. to develop a treatment for an inherited form of bowel tumour (Familial Adenomatous Polyposis (FAP)). The treatment will incorporate Cobra's proprietary antibiotic free maintenance technology (ORT) in conjunction with Cequent's proprietary TransKingdom RNA interference (tkRNAi) technology. Commenting on the contract, David Thatcher, CEO at Cobra, said: "We are delighted to work with Cequent on this exciting project. Interference RNA (RNAi) has great potential for medicine, and Cequent's tkRNAi technology clearly represents an important breakthrough for the difficult, but exciting field of RNAi delivery. We believe the combination of Cobra's ORT technology with Cequent's in vivo delivery platform will have significant clinical benefit." Peter Parker, President and CEO at Cequent, said: "Cobra has an excellent track record of developing innovative solutions for molecular biology and biologic therapy, and we look forward to collaborating with Cobra's outstanding scientific team to evaluate their ORT technology for use in our therapeutic tkRNAi bacteria." Notes for Editors About RNAi: RNAi can potently and selectively silence any cellular gene or combination of genes, making it an ideal approach to influence the behavior of cells where the role of individual proteins is known. One, or more than one, gene can be simultaneously silenced. The knowledge of the human genome allows the progressive identification of disease-causing genes. RNA interference offers a novel and highly efficient tool to block the expression of such disease-causing genes. RNAi-based therapies are expected to offer novel treatment solutions for a multitude of gene-based disease states, including cancer, inflammatory disease, and viruses. About FAP: Familial adenomatous polyposis: Abbreviated FAP. A genetic syndrome characterized by the formation of hundreds of polyps in the colon and rectum with colorectal cancer the inevitable consequence. 1:10,000 people are affected in the United States. Polyps can also occur in the stomach, duodenum and the terminal ileum. Patients require frequent removal of polyps via endoscopy and often the entire colon is removed after puberty to avoid colon cancer formation. ORT(R) Technology ORT is a way of creating totally stable genetically engineered strains of micro-organisms without the use of antibiotics or antibiotic genes. Other technologies rely on either integrating the synthetic gene(s) into the bacterial chromosome or using antibiotics and antibiotic resistance genes to amplify replicating mini-chromosomes (called plasmids) containing the new genes. In the vaccine field it has been known for 10 years that the former approach leads to poor strain productivity and the latter to strain instability. Use of antibiotics also creates the risk of passing on the antibiotic resistance genes to pathogens in the environment. Such events have occurred naturally to create MRSA super bug strains so ORT(R) strains are inherently safer for patients. ORT(R) technology avoids these problems. Live Oral ORT Technology This application harnesses the advantages of conventional genetic engineering with the safer ORT(R) strain stabilisation technology. This allows rapid and simple construction of bacterial strains, capable of expressing massive quantities of synthetic DNA, protein or RNA that can lead to beneficial effects against disease targets without the fear of creating antibiotic resistant strains which might be difficult to manage clinically. About Cequent Pharmaceuticals Inc Cequent Pharmaceuticals, Inc. is an early-stage biopharmaceutical company developing new clinically compatible therapies based on RNA interference (RNAi). Cequent is focusing its efforts on the pre-clinical development of products to treat gastrointestinal diseases, including familial adenomatous polyposis (FAP), inflammatory bowel disease and colon cancer. Cequent has an exclusive license to a new technology, transkingdom RNA-Interference (tkRNAi), which was invented and developed over the past 5 years at the GI Cancer Laboratory of Beth Israel Deaconess Medical Center, Harvard Medical School. In this technique, non-pathogenic bacteria are used as engines to simultaneously produce and deliver RNAi. Through its use of tkRNAi in various gastrointestinal diseases, Cequent is developing a portfolio of novel therapeutic applications for RNAi - one of the most promising medical breakthroughs of this decade. About Cobra Biomanufacturing Plc Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products. Cobra was the first company to develop and gain GMP (Good Manufacturing Practice) standard DNA manufacture in Europe, with specific expertise in DNA medicines. A range of unique, patented technologies, underpins this revenue generating business. Cobra floated on the Alternative Investment Market of the London Stock Exchange in June 2002 raising #7 million and raised a further #5.2 million in May 2003 in order to further expand capacity in Oxford UK. www.cobrabio.com Statements contained within this press release may contain forward-looking comments which involve risks and uncertainties that may cause actual results to vary from those contained in the forward-looking statements. In some cases, you can identify such forward-looking statements by terminology such as 'may', ' will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', ' estimates', 'predicts', 'potential', or 'continue'. Predictions and forward-looking references in this press release are subject to the satisfactory progress of research, which is, by nature, unpredictable. Forward projections reflect management's best estimates based on information available at the time of issue. For further information, please contact: Cobra Biomanufacturing Plc Tel: +44 (0) 1782 714 181 David Thatcher, Chief Executive Peter Coleman, Finance Director Buchanan Communications Tel: +44 (0) 207 466 5000 Tim Anderson/Mark Court/Rebecca Skye Dietrich Cequent Pharmaceuticals, Inc Tel: +1 (781) 771-5579 Caroline Grossman caroline.grossman@gmail.com This information is provided by RNS The company news service from the London Stock Exchange END NRAEAKFXFSEXEFE
1 Year Cobra Bio-manufacturing Chart |
1 Month Cobra Bio-manufacturing Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions